Findings of a new study reinforce previous conclusions that higher THC concentrations increase the risk for adverse mental health outcomes, but researchers say more studies needed.
RT’s Three Key Takeaways:
- High-THC cannabis products are linked to mental health risks, with strong associations to psychosis, schizophrenia, and cannabis use disorder.
- Evidence on anxiety and depression is mixed, as some studies suggest potential therapeutic benefits while many others report unfavorable effects.
- Researchers call for stronger studies, noting current evidence is limited and insufficient to provide clear clinical guidance.
High-concentration delta-9-tetrahydrocannabinol (THC) cannabis products are associated with unfavorable mental health outcomes, particularly for psychosis or schizophrenia and cannabis use disorder (CUD), according to a systematic review published in Annals of Internal Medicine. However, researchers say there are limitations to currently available evidence and call for studies with improved designs to provide more accurate guidance for clinicians and the public.
Researchers from University of Colorado Anschutz Medical Campus and colleagues analyzed 99 studies comprising 221,097 participants completed between 1977 and 2023. Study selection was intentionally broad and included studies examining associations between high-concentration cannabis products and mental health outcomes regardless of whether the study had the purpose of evaluating therapeutic effects.
High-concentration cannabis products were defined as having THC concentration exceeding 5 mg THC or 10% THC per serving or products described as “high-potency concentrate,” “shatter,” or “dab.”
The mental health outcomes of interest included anxiety, depression, psychosis, schizophrenia, CUD and other substance use disorders. The researchers defined acute effects (within 12 hours), post-acute effects (after consistent use for 1 to 2 months), and long-term effects (after consistent use for > 1 year).
In studies not testing for therapeutic effects, high concentration THC products were associated with psychosis, schizophrenia, and cannabis use disorder. No therapeutic studies found favorable effects on psychosis or schizophrenia. Of non-therapeutic studies, 53% identified unfavorable associations with anxiety and 41% found unfavorable associations with depression. Among therapeutic studies, some suggested beneficial effects for anxiety (47%) and depression (48%), while others suggested unfavorable effects (24% for anxiety and 30% for depression).
“The findings reinforce previous conclusions that higher THC concentrations increase the risk for adverse mental health outcomes; however, they fall short of providing the definitive evidence needed to provide clear advice to patients,” according to researchers.
